Soligenix, Inc. (SNGX)
Automate Your Wheel Strategy on SNGX
With Tiblio's Option Bot, you can configure your own wheel strategy including SNGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNGX
- Rev/Share 0.0008
- Book/Share 1.1846
- PB 1.3929
- Debt/Equity 0.0219
- CurrentRatio 11.256
- ROIC -1.4049
- MktCap 5386178.0
- FreeCF/Share -2.7556
- PFCF -0.6409
- PE -0.7923
- Debt/Assets 0.0102
- DivYield 0
- ROE -1.483
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.
Read More
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025.
Read More
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of CiVax™, a thermostabilized subunit vaccine against SARS-CoV-2.
Read More
About Soligenix, Inc. (SNGX)
- IPO Date 1994-04-04
- Website https://www.soligenix.com
- Industry Biotechnology
- CEO Dr. Christopher J. Schaber Ph.D.
- Employees 14